GEN Exclusives

More »

GEN News Highlights

More »
Sep 18, 2013

Florida Hospital to Evaluate VTT’s Alzheimer’s Biomarker Assay

  • VTT Technical Research Centre of Finland is taking an important step toward advancing its Alzheimer’s disease biomarker by collaborating with the Florida Hospital Neuroscience Institute to evaluate screening, diagnostic, and prognostic potential of the biomarker assay and utilize it to specifically target which types of precautions to take when approaching early stages of the disease.

    A serum biochemical signature that predicts progression to Alzheimer’s disease was previously developed by scientists from VTT and the University of Eastern Finland. As a result of the collaboration, VTT was able to develop a biomarker assay, according to the company.

    Earlier this week, VTT announced partnership in a consortium focused on creating new diagnostic and bioinformatics tools for psychotic disorders with the overall objective to identify, prioritize, and evaluate multi-modal blood and neuroimaging biomarkers that have diagnostic potential for prediction and monitoring psychotic disorders and associated metabolic comorbidities.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?